Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16883242 | 0.95 | LMNA (0.49) | LMNACYP2C19HIF1A | |
| Ioforminol SCHEMBL374830 | 0.90 | LMNA (0.65) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL8587003 | 0.90 | CYP2C19 (0.65) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL2763827 | 0.88 | LMNA (0.60) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL3783951 | 0.86 | LMNA (0.60) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL19645487 | 0.85 | LMNA (0.61) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL8583797 | 0.85 | CYP2C19 (0.60) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL14478600 | 0.85 | LMNA (0.63) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL19261514 | 0.84 | LMNA (0.60) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL1742986 | 0.84 | LMNA (0.59) | LMNACYP2C19HIF1AEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150191422-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2015-07-09 | — | — | US | disclosed |
| US-20150191422-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2015-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191422-A1 | CONTRAST AGENTS | SSTR3, INSR, INSRR | LMNA 1656/4885CYP2C19 3523/4885HIF1A 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.